Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, cross-over, 4-period, 4 treatment, with-subject placebo-controlled study to assess the optimal renoprotective dose of aliskiren in hypertensive type 2 diabetic patients with incipient or overt nephropathy

Next Previous
X
Search
Trial Profile

A randomized, double-blind, cross-over, 4-period, 4 treatment, with-subject placebo-controlled study to assess the optimal renoprotective dose of aliskiren in hypertensive type 2 diabetic patients with incipient or overt nephropathy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2011

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Diabetic nephropathies; Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 03 Feb 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 22 Jun 2008 The expected completion date for this trial has been extended from May 2008 to July 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top